No Data
Southern Model Biology (688265.SH): The actual controller has renewed the concerted action agreement.
On December 27, Gelonghui reported that Nanmo Biological (688265.SH) announced the receipt of a notice from its actual controllers, Mr. Fei Jian and Mr. Wang Mingjun, regarding the renewal of the concerted action agreement set to expire. In view of the impending expiration of the concerted action agreement and its supplementary agreement signed prior to the company's initial public offering of Stocks, both parties have renewed the "Concerted Action Agreement (2024)" to ensure the continuity and stability of the company's Operation and to achieve substantive and effective control over the company.
Nanmo Biology: third quarter report 2024
Third Quarter Report 2024
Nanom (688265.SH) released its performance for the first three quarters, with a net loss of 15.1954 million yuan.
Nanmo Biotech (688265.SH) released the report for the first three quarters of 2024, during which the company achieved revenue...
Nanmo Biology (688265.SH): The net loss in the first three quarters was 15.195 million yuan.
Nanomodel Biology (688265.SH) released its third-quarter report on October 30th. The revenue for the first three quarters was 0.26 billion yuan, a 1.17% year-on-year decrease. The net loss was 15.195 million yuan, with a non-net loss of 32.27 million yuan, and basic earnings per share was -0.20 yuan.
The downstream cooling effect impacted the performance. Namoo Bioscience plans to increase production capacity utilization and overseas become a 'key development focus' | Directly hitting the earnings conference.
①Affected by the unfavorable investment and financing situation of downstream industrial customers, Nanmo Biotechnology has been under continuous pressure on performance in recent years. Chairman Fei Jian disclosed that the overall utilization rate of domestic production capacity is close to 80%, and will further improve the capacity utilization rate in the future; ②In the first half of 2024, the proportion of overseas business income has increased to 14%. Fei Jian frankly stated that overseas expansion is a key focus, and in the second half of the year, will continue to optimize the overseas BD team development.
Unpleasant Surprises Could Be In Store For Shanghai Model Organisms Center, Inc.'s (SHSE:688265) Shares
